Drug shortage: Morphine Sulfate Injection (DURAMORPH, MORPHINE SULFATE, MITIGO)
FDA lists 24 presentations as Current. Availability: Unavailable (6), Limited Availability (2), Available (16). Reason: Discontinuation of the manufacture of the drug; Other. Companies: Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company, Fresenius Kabi USA, LLC, Piramal Critical Care Inc., Amphastar Pharmaceuticals, Inc..
- Published by source
- 2017-10-31
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-23
Affected
- Manufacturer
- Hikma Pharmaceuticals USA, Inc.
- Products
- Morphine Sulfate Injection DURAMORPH MORPHINE SULFATE MITIGO INFUMORPH 200 INFUMORPH 500
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Additional lots are scheduled to be manufactured. Product will be made available as it is released.
- Discontinuation of the manufacture of the drug
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2017-10-31
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #895 | new | 2026-10-22 | 6ac9d91d7bd6…c9a13d | 6bc5bce651f0…52c5af |
| #1128 | update | 2026-10-23 | 8bba8904d75d…9924cf | 75669bdca7f6…c00263 |
Chain head: #1250 0c9a4a81d7d8…29590d